Novartis acquire Calypso for $425 million to develope CALY-002 - an auto immune anti inflammatory targeting IL-15 and its presently in a phase1b
https://www.pharmtech.com/view/novartis-acquires-calypso-biotech-for-up-to-425-million
675A with data out of a Phase III
same same 42X
pretty simple to work out what is coming for these 2